Úlcera péptica

  1. C. Carretero 1
  1. 1 Clínica Universitaria de Navarra
    info

    Clínica Universitaria de Navarra

    Pamplona, España

    ROR https://ror.org/03phm3r45

Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2016

Título del ejemplar: Enfermedades del aparato digestivo (III): Patología gastroduodenal (II)

Serie: 12

Número: 3

Páginas: 111-117

Tipo: Artículo

DOI: 10.1016/J.MED.2016.02.001 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Objetivos de desarrollo sostenible

Resumen

Introduction. Aetiopathogenesis Peptic ulcer disease is a common condition, generally caused by Helicobacter pylori infection or nonsteroidal anti-inflammatory drugs. Clinical manifestations Patients with peptic ulcer disease may not have symptoms but when symptoms occur, the most common one is epigastric abdominal pain. Diagnosis To confirm the diagnosis, an upper endoscopy should be performed. Treatment Treatment of peptic ulcers always includes antisecretory therapy and antibiotic treatment if peptic ulcer disease is caused by H. pylori infection. Complications In some cases ulcers may be complicated in the form of bleeding or perforation, requiring also endoscopic or surgical treatment. Conclusion This paper reviews the etiology, clinical manifestations, complications, diagnosis and treatment of peptic ulcer.

Referencias bibliográficas

  • Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther. 2009;29(9):938-46.
  • García Rodríguez LA, Hernández-Díaz S. Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol. 2004;159(1):23-31.
  • Rosenstock SJ, Jorgensen T, Bonnevie O, Andersen LP. Does Helicobacter pylori infection explain all socio-economic differences in peptic ulcer incidence? Genetic and psychosocial markers for incident peptic ulcer disease in a large cohort of Danish adults. Scand J Gastroenterol. 2004;39(9):823-9.
  • Sonnenberg A. Temporal trends and geographical variations of peptic ulcer disease. Aliment Pharmacol Ther. 1995;9Suppl2:3-12.
  • Ciociola AA, McSorley DJ, Turner K, Sykes D, Palmer JB. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol. 1999;94(7):1834-40.
  • Chiorean MV, Locke GR, 3rd, Zinsmeister AR, Schleck CD, Melton LJ, 3rd. Changing rates of Helicobacter pylori testing and treatment in patients with peptic ulcer disease. Am J Gastroenterol. 2002;97(12):3015-22.
  • Jyotheeswaran S, Shah AN, Jin HO, Potter GD, Ona FV, Chey WY. Prevalen-ce of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified? Am J Gastroenterol. 1998;93(4):574-8.
  • Blaser MJ. Not all Helicobacter pylori strains are created equal: should all be eliminated? Lancet. 1997;349(9057):1020-2.
  • Barkun A, Leontiadis G. Systematic review of the symptom burden, quality of life impairment and costs associated with peptic ulcer disease. Am J Med. 2010;123(4):358-66.e2.
  • Gururatsakul M, Holloway RH, Talley NJ, Holtmann GJ. Association between clinical manifestations of complicated and uncomplicated peptic ulcer and visceral sensory dysfunction. J Gastroenterol Hepatol. 2010;25(6):1162-9.
  • Dooley CP, Larson AW, Stace NH, Renner IG, Valenzuela JE, Eliasoph J, et al. Double-contrast barium meal and upper gastrointestinal endoscopy. A comparative study. Ann Intern Med. 1984;101(4):538-45.
  • Graham DY, Schwartz JT, Cain GD, Gyorkey F. Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. Gas-troenterology. 1982;82(2):228-31.
  • Gisbert JP, Calvet X, Bermejo F, Boixeda D, Bory F, Bujanda L, et al. III Conferencia Española de Consenso sobre la infección por Helicobacter pylori. Gastroenterología y Hepatología. 2013;36:340-74.
  • Lau JY, Sung J, Hill C, Henderson C, Howden CW, Metz DC. Syste-matic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion. 2011;84(2): 102-13.
  • Santolaria S, Lanas A, Benito R, Pérez-Aisa M, Montoro M, Sainz R. Helico-bacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users. Aliment Pharmacol Ther. 1999; 13(11):1511-8.
  • Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56(6):772-81.
  • Gisbert JP, Pajares JM. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol Ther. 2005;21(7):795-804.
  • Lau JY, Leung WK, Wu JC, Chan FK, Wong VW, Chiu PW, et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med. 2007;356(16):1631-40.
  • Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malferthei-ner P. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther. 2001;15(12):1949-58.
  • Gisbert JP, Khorrami S, Carballo F, Calvet X, Gene E, Domínguez-Muñoz E. Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther. 2004;19(6):617-29.
Fuente de los datos: Dialnet